Cardea Bio raises $7.5 million in series A2 financing
Following a $7.8 Million Series A-1 financing announced in March 2019, Cardea, (formerly called Nanomedical Diagnostics), a U.S-based manufacturer of a biology-enabled transistor technology made from graphene-based biosensors, now announced another $7.5 Million raised in the Series A2 Financing.
The capital will help accelerate the growth and development of the Company’s proprietary Tech+Bio Infrastructure and chipsets that enable Cardea’s Innovation Partners to bring Powered by Cardea" products to market with features and competitive advantages Cardea defines as "never seen before".